Skip to Content
Merck
CN

45720

Eserine salicylate salt

≥97.0% (N)

Synonym(s):

Physostigmine salicylate salt

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C15H21N3O2 · C7H6O3
CAS Number:
Molecular Weight:
413.47
EC Number:
200-343-8
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
3900576
MDL number:
Assay:
≥97.0% (N)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

HZOTZTANVBDFOF-PBCQUBLHSA-N

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1

SMILES string

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

biological source

synthetic

assay

≥97.0% (N)

form

powder

optical activity

[α]20/D −77±2°, c = 1% in ethanol

mp

181-183 °C

Biochem/physiol Actions

Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Rubnov et al.
Journal of pharmaceutical and biomedical analysis, 18(6), 939-945 (1999-01-30)
A simple stability-indicating HPLC assay has been developed for physostigmine salicylate, capable of following its degradation. A 250 x 5 mm i.d. column packed with 10 microm Bondapak C18 was used, with a mobile phase of acetonitrile - ammonium acetate
D K Lim et al.
Pharmacology, biochemistry, and behavior, 31(3), 627-631 (1988-11-01)
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in guinea pigs. Both blood and brain cholinesterase activity
F H Norris et al.
Clinical pharmacology and therapeutics, 54(6), 680-682 (1993-12-01)
We evaluated a double-blind, placebo-controlled, and double-crossover trial of oral physostigmine salicylate for a 9-month period in 13 of 25 patients with sporadic amyotrophic lateral sclerosis (ALS). A large dropout rate of 48% was secondary to eight deaths and four
M H Rapaport et al.
Biological psychiatry, 29(7), 658-664 (1991-04-01)
Nine patients who met both DSM-III and RDC criteria for panic disorder and nine age-matched normal controls received infusions of physostigmine. The patients and normal controls did not differ in either their self-reported or the observer-reported ratings of anxiety, mood
N M Rupniak et al.
Behavioural brain research, 43(1), 1-6 (1991-04-18)
A scopolamine-like delay-dependent impairment in spatial delayed response performance in rhesus monkeys was induced by irrelevant interpolated activity or by using extended retention intervals. Physostigmine readily reversed the effects of scopolamine but had no effect on performance in young monkeys

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service